CY1112605T1 - Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων - Google Patents

Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων

Info

Publication number
CY1112605T1
CY1112605T1 CY20111100984T CY111100984T CY1112605T1 CY 1112605 T1 CY1112605 T1 CY 1112605T1 CY 20111100984 T CY20111100984 T CY 20111100984T CY 111100984 T CY111100984 T CY 111100984T CY 1112605 T1 CY1112605 T1 CY 1112605T1
Authority
CY
Cyprus
Prior art keywords
active
ketotifaine
iseter
visually
hydroxy
Prior art date
Application number
CY20111100984T
Other languages
Greek (el)
English (en)
Inventor
A K Gunnar Aberg
George E Wright
Jan L Chen
Andrew T Maioli
Original Assignee
Bridge Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma, Inc. filed Critical Bridge Pharma, Inc.
Publication of CY1112605T1 publication Critical patent/CY1112605T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20111100984T 1999-09-13 2011-10-17 Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων CY1112605T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15356699P 1999-09-13 1999-09-13
US19736300P 2000-04-15 2000-04-15
US19798500P 2000-04-15 2000-04-15
US19790600P 2000-04-15 2000-04-15
US19790500P 2000-04-15 2000-04-15
EP00966709A EP1218007B1 (en) 1999-09-13 2000-09-12 Optically active isomers of ketotifen and therapeutically active metabolites thereof

Publications (1)

Publication Number Publication Date
CY1112605T1 true CY1112605T1 (el) 2016-02-10

Family

ID=27538454

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100984T CY1112605T1 (el) 1999-09-13 2011-10-17 Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων

Country Status (18)

Country Link
US (3) US7226934B1 (https=)
EP (1) EP1218007B1 (https=)
JP (1) JP5116928B2 (https=)
CN (1) CN1391475A (https=)
AR (1) AR034396A1 (https=)
AT (1) ATE516804T1 (https=)
AU (1) AU782816B2 (https=)
BR (1) BR0013935A (https=)
CA (1) CA2383222C (https=)
CY (1) CY1112605T1 (https=)
DK (1) DK1218007T3 (https=)
HU (1) HUP0202671A3 (https=)
IL (2) IL148368A0 (https=)
MX (1) MXPA02002658A (https=)
MY (1) MY134888A (https=)
PL (1) PL353586A1 (https=)
PT (1) PT1218007E (https=)
WO (1) WO2001019367A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226934B1 (en) * 1999-09-13 2007-06-05 Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US9006210B2 (en) 2008-06-13 2015-04-14 Case Western Reserve University Compositions and methods for treating corneal inflammation
WO2010047681A1 (en) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
AU2010226249A1 (en) * 2009-03-17 2011-10-13 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
JP5978296B2 (ja) * 2011-06-28 2016-08-24 フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド 抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US9345697B2 (en) * 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9138431B2 (en) * 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
CN104059056B (zh) * 2014-06-26 2017-08-25 福建省闽东力捷迅药业有限公司 一种富马酸卢帕替芬晶型b及其制备方法
CA2988564C (en) * 2015-06-11 2021-10-05 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus in mammals
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
WO2018048989A1 (en) 2016-09-08 2018-03-15 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of hypercytokinemia and viral infection
EP3528809A4 (en) 2016-10-18 2020-06-10 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1089483A (en) 1964-02-04 1967-11-01 Sandoz Ltd Improvements in or relating to 4h-benzo(4,5)cyclohepta (1,2-b) thiophene derivatives
FR1447527A (fr) 1964-08-11 1966-07-29 Sandoz Sa Nouveaux benzo-cyclohepta-thiophènes et leur préparation
CH531000A (de) * 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
BE794377A (fr) * 1972-01-24 1973-07-23 Sandoz Sa Nouveaux derives du benzo-cyclohepta-thiophene
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4073915A (en) 1975-05-20 1978-02-14 Sandoz Ltd. Treating asthma
US4128549A (en) 1976-02-27 1978-12-05 Sandoz Ltd. Precursors of 4-(1-alkyl-4-piperidylidene-4H-benzo[4,5]cyclohepta-[1,2-b]thiophen-10(9H)-ones
CS263993B1 (cs) 1988-03-11 1989-05-12 Polivka Zdenek Způsob přípravy čistých enantiomerů 4- (l-meíhyl-4-piperidyliden) -4,9-dihydrobenzo [ 4,5) cyklohepta [ 1,2-b ] - thiofen-lQ-onu
SG44477A1 (en) 1988-04-28 1997-12-19 Schering Corp Fused polycyclic compounds compositions methods of manufacture and their use as paf antaginists anthihistamines and/or antiinflammatory agents
GB9012926D0 (en) * 1990-06-09 1990-08-01 Scras Pyrrolo-pyridine derivatives
AU8854091A (en) * 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
DK0616524T3 (da) * 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
ES2172510T3 (es) * 1991-12-18 2002-10-01 Astrazeneca Ab Nueva combinacion de formoterol y budesonida.
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1998043640A1 (en) 1997-04-03 1998-10-08 Bridge Pharma, Inc. Benzocycloheptathiophene compounds
EP1014979A4 (en) * 1997-06-09 2003-08-20 Bridge Pharma Inc CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE
US7226934B1 (en) * 1999-09-13 2007-06-05 Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof

Also Published As

Publication number Publication date
CA2383222A1 (en) 2001-03-22
BR0013935A (pt) 2002-05-14
JP5116928B2 (ja) 2013-01-09
MXPA02002658A (es) 2002-10-23
EP1218007A1 (en) 2002-07-03
AR034396A1 (es) 2004-02-25
EP1218007A4 (en) 2003-04-09
CA2383222C (en) 2008-11-18
ATE516804T1 (de) 2011-08-15
WO2001019367A1 (en) 2001-03-22
DK1218007T3 (da) 2011-11-07
US20090149502A1 (en) 2009-06-11
IL148368A0 (en) 2002-09-12
EP1218007B1 (en) 2011-07-20
PL353586A1 (en) 2003-12-01
CN1391475A (zh) 2003-01-15
MY134888A (en) 2007-12-31
US7557128B2 (en) 2009-07-07
AU782816B2 (en) 2005-09-01
PT1218007E (pt) 2011-10-27
HUP0202671A3 (en) 2005-01-28
HUP0202671A2 (hu) 2002-11-28
JP2003509369A (ja) 2003-03-11
US20080287498A1 (en) 2008-11-20
US7226934B1 (en) 2007-06-05
US7872025B2 (en) 2011-01-18
IL148368A (en) 2007-10-31
AU7701400A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
CY1112605T1 (el) Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων
CY1119029T1 (el) Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
ATE234092T1 (de) 2-alkylpyrrolidine
ATE358479T1 (de) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro- imidazol-2-thion als nicht-sedierender alpha 2a agonist
NO20013443D0 (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
NO976074L (no) To- og treverdige småmolekylinhibitorer for selektin
TR199900400T2 (xx) Heterosiklik metaloproteaz inhibit�rleri.
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
TR199900383T2 (xx) 1,3-Diheterosiklik metaloproteaz inhibit�rleri.
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
UY26380A1 (es) Inhibidores de fab i
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE69916792D1 (de) Kaliumkanalblocker
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
TR199900429T2 (xx) Spirosiklik metaloproteaz inhibit�rleri.
NO20042497L (no) 4,4-diflour-1,2,3,4-tetrahydro-5H-1-benzazepinderivater og salter av disse
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
IT1295933B1 (it) 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
EA200100854A1 (ru) Кальций-литические соединения